Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.

Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V, DUPRO steering committee and PROTECT Investigators.

Open source

DOI: 10.1016/s0140-6736(23)02302-4
Published: 2023-11-03
Container: Lancet
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-23-02302-4,
  title = {Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.},
  author = {Rovin BH and  Barratt J and  Heerspink HJL and  Alpers CE and  Bieler S and  Chae DW and  Diva UA and  Floege J and  Gesualdo L and  Inrig JK and  Kohan DE and  Komers R and  Kooienga LA and  Lafayette R and  Maes B and  Małecki R and  Mercer A and  Noronha IL and  Oh SW and  Peh CA and  Praga M and  Preciado P and  Radhakrishnan J and  Rheault MN and  Rote WE and  Tang SCW and  Tesar V and  Trachtman H and  Trimarchi H and  Tumlin JA and  Wong MG and  Perkovic V and  DUPRO steering committee and PROTECT Investigators.},
  year = {2023},
  journal = {Lancet},
  doi = {10.1016/s0140-6736(23)02302-4},
  url = {https://doi.org/10.1016/s0140-6736(23)02302-4}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
AU  - Rovin BH
AU  -  Barratt J
AU  -  Heerspink HJL
AU  -  Alpers CE
AU  -  Bieler S
AU  -  Chae DW
AU  -  Diva UA
AU  -  Floege J
AU  -  Gesualdo L
AU  -  Inrig JK
AU  -  Kohan DE
AU  -  Komers R
AU  -  Kooienga LA
AU  -  Lafayette R
AU  -  Maes B
AU  -  Małecki R
AU  -  Mercer A
AU  -  Noronha IL
AU  -  Oh SW
AU  -  Peh CA
AU  -  Praga M
AU  -  Preciado P
AU  -  Radhakrishnan J
AU  -  Rheault MN
AU  -  Rote WE
AU  -  Tang SCW
AU  -  Tesar V
AU  -  Trachtman H
AU  -  Trimarchi H
AU  -  Tumlin JA
AU  -  Wong MG
AU  -  Perkovic V
AU  -  DUPRO steering committee and PROTECT Investigators.
PY  - 2023
JO  - Lancet
DO  - 10.1016/s0140-6736(23)02302-4
UR  - https://doi.org/10.1016/s0140-6736(23)02302-4
ER  -

APA

BH, R., J, B., HJL, H., CE, A., S, B., DW, C., UA, D., J, F., L, G., JK, I., DE, K., R, K., LA, K., R, L., B, M., R, M., A, M., IL, N., SW, O., CA, P., M, P., P, P., J, R., MN, R., WE, R., SCW, T., V, T., H, T., H, T., JA, T., MG, W., V, P., & Investigators., D. S. C. A. P. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.. Lancet. https://doi.org/10.1016/s0140-6736(23)02302-4

Source records

europe-pmc · retrieved 2026-09-26T03:24:16.263Z
hal · retrieved 2026-09-26T03:24:16.304Z